SUBSCRIBE
SUBSCRIBE
News   Drug Development

DiaKine Therapeutics, Inc. Drug Improves Type 2 Insulin Action; Reduces Harm of Fat in Preclinical Study

January 22, 2009 | 
1 min read
BANFF, Alberta--(BUSINESS WIRE)--Results of a preclinical study involving DiaKine Therapeutics’ lead drug candidate Lisofylline (LSF) indicate the compound may reduce two key risk factors for type 2 diabetes.
Preclinical
MORE ON THIS TOPIC
female hand hold human brain on yellow background.
Alzheimer’s disease
Roche’s Next-Gen Alzheimer’s Antibody Clears or Reduces Amyloid Plaques in Seven Months
July 28, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Schizophrenia
Atai-Partnered Schizophrenia Drug Flunks Mid-Stage Trial
July 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Dollars as a global currency, loan, credit, and payment concept. A hand offering 100 US dollars. Minimalist art collage
Collaboration
Eli Lilly Commits $856M in Biobucks to Gate Bioscience for New Class of Medicines
July 25, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Facade of AstraZeneca's office in Shanghai, China
Autoimmune disease
AstraZeneca Claims PIII Win With Nanobody Treatment for Myasthenia Gravis
July 24, 2025
 · 
2 min read
 · 
Dan Samorodnitsky